Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAT atypical cadherin 2 is a giant cell surface protein belonging to the cadherin superfamily, containing 34 tandem cadherin repeats, two epidermal growth factor (EGF)-like repeats, and one laminin G domain[2][3][7]. FAT2 acts as a cell adhesion molecule implicated in the regulation of cell proliferation, planar cell polarity, tissue morphogenesis, and development, notably in the cerebellum[2][3][4]. FAT2’s role includes organizing parallel fibers in granule cells during cerebellar development and regulating cell migration[3]. Pathologically, mutations or loss of FAT2 have been linked to tumorigenesis through disruption of the Hippo pathway and are associated with neurological disorders such as spinocerebellar ataxia[1][3]. FAT2’s paralog, FAT1, and related family members share overlapping functions in cytoskeletal organization, adhesion, and developmental processes[3][4]. Although not currently a druggable target, its involvement in cell signaling and cancer makes it a candidate for future therapeutic exploration[2][3].
Not established for drugs; therapeutics would theoretically modulate cell adhesion, signaling or proliferation via FAT2 activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FAT atypical cadherin 2 (FAT2).